Dendritic Cell Cancer Vaccine Market Is Likely to Experience a Tremendous Growth by 2029
The global dendritic cell cancer vaccine market is anticipated to grow at a significant CAGR during the forecast period. The major factors that are expected to boost the market include an increase in the prevalence of cancer, improvement of technology such as drug innovations regarding cancer, an upsurge in awareness about cancer and their available therapies in the market. Dendritic cells (DCs) are one of the major antigen-presenting cells found in lymphoid organs. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells. The main function of the dendritic cells is antigen display and activation of T-cells. Antigen display presents the identity of the pathogen to T-cells for their identification and elimination from the body. They are rare kinds of leukocytes. Isolated dendritic cells (DCs) loaded with tumor antigen ex vivo and administered as a cellular vaccine are found to induce protective and therapeutic anti-tumor immunity in experimental animals.
Some other factors that are expected to fuel the
market growth include the rise in investments in R&D activities, together
with positive results in clinical trials, which are anticipated to drive the
growth of the market. Other factors that are boosting the growth of the market
include the ability of dendritic cells to target multiple cancer antigen
capability, a rise in the geriatric population, and technological advancements.
Currently, the three marketed cancer vaccines commercially available in
different geographies include Provenge (U.S.), CreaVax-RCC (South Korea), and
Tumor Antigen Presenting Cells, such as TAPCells (Chile). Provenge is the first
marketed dendritic cell vaccine available in the market. They are targeted to
treat prostate cancer, metastatic renal cell carcinoma, melanoma, and prostate
cancer.
To Request a Sample of our Report on Dendritic Cell
Cancer Vaccine Market: https://www.omrglobal.com/request-sample/dendritic-cell-cancer-vaccine-market
Market Coverage
• The market number available for – 2022-2029
• Base year- 2022
• Forecast period- 2023-2029
Segment Covered-
·
By Product Type
·
By End-Users
Regions covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
·
Competitive Landscape: Argos
Therapeutics, and Dendreon Corp., among others
Dendritic Cell Cancer Vaccine Market Report by Segment
By Product Type
• CreaVax
• Sipuleucel-T (Provenge)
• Others
By End-Users
• Adults
• Pediatrics
A
full Report of Dendritic Cell Cancer Vaccine Market is Available @ https://www.omrglobal.com/industry-reports/dendritic-cell-cancer-vaccine-market
Dendritic Cell Cancer Vaccine Market
Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a
market research and consulting company known for its crisp and concise reports.
The company is equipped with an experienced team of analysts and consultants.
OMR offers quality syndicated research reports, customized research reports, consulting
and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services
through another subsidiary Encanto
Technologies.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment